venBio Partners’s ACELYRIN SLRN Stock Holding History

venBio Partners’s Portfolio SLRN Stock Details SLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-3,806,410	Closed	-$9.4M	–	7
2025 Q1	$9.4M	Hold	3,806,410	–	–	7.61%	4
2024 Q4	$12M	Sell	3,806,410 -46,060	-1%	-$223K	7%	6
2024 Q3	$19M	Hold	3,852,470	–	–	9.77%	5
2024 Q2	$17M	Hold	3,852,470	–	–	7.34%	5
2024 Q1	$26M	Hold	3,852,470	–	–	9.23%	4
2023 Q4	$28.7M	Hold	3,852,470	–	–	4.31%	5
2023 Q3	$39.2M	Sell	3,852,470 -4,760	-0.1%	-$101K	11.11%	4
2023 Q2	$80.6M	Buy	+3,857,230	New	+$78.9M	29.18%	1

Other funds holding SLRN

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

venBio Partners's SLRN Position: Q2 2025 in Review

venBio Partners sold out of ACELYRIN (SLRN) in Q2 2025, closing a stake of 3,806,410 shares — an estimated $9.4M sold.

venBio Partners first reported a position in SLRN in Q2 2023 and held it in 8 quarters. The position peaked at $80.6M in Q2 2023. 2 funds tracked by Wall St. Rank hold SLRN as of Q2 2025.

venBio Partners reported no remaining ACELYRIN position as of Q2 2025 after selling out during the quarter.
venBio Partners sold 3,806,410 ACELYRIN shares in Q2 2025, an estimated $9.4M.
venBio Partners first reported a position in ACELYRIN in Q2 2023 and held it in 8 quarters.
venBio Partners's ACELYRIN position peaked at $80.6M in Q2 2023.
2 funds tracked by Wall St. Rank held ACELYRIN as of Q2 2025.

Based on venBio Partners's 13F filing for Q2 2025, filed 14 Aug 2025.